Last reviewed · How we verify
Anti TNF Alfa.
Anti TNF Alfa works by binding to and inhibiting tumor necrosis factor-alpha, a cytokine involved in systemic inflammation.
Anti TNF Alfa works by binding to and inhibiting tumor necrosis factor-alpha, a cytokine involved in systemic inflammation. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | Anti TNF Alfa. |
|---|---|
| Also known as | HUMIRA-ADALIMUMAB, REMICADE-INFLIXIMAB |
| Sponsor | Carmel Medical Center |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
This binding prevents TNF-alpha from interacting with its receptors on cell surfaces, thereby reducing inflammation and halting disease progression. Anti TNF Alfa is a type of biologic therapy that targets the immune system's response to inflammation.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Crohn's disease
- Ulcerative colitis
Common side effects
- Injection site reaction
- Headache
- Fatigue
- Muscle pain
- Nausea
Key clinical trials
- Apremilast for RAS (PHASE4)
- Enthesitis Assessment Before and After Anti-Tumor Necrosis Factor Treatment in Spondyloarthritis (PHASE4)
- Effect of Preoperative Anxiety on Fetus in Pregnant Women
- NGF, TrKA,p75NTR in Men With ED and Diabetes With or Without MS (NA)
- SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy (PHASE3)
- Anti TNF α Improves Endothelial Dysfunction in IBD Patients
- ADALISKIAS: Adalimumab for Acute Disc Prolapse (PHASE3)
- Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti TNF Alfa. CI brief — competitive landscape report
- Anti TNF Alfa. updates RSS · CI watch RSS
- Carmel Medical Center portfolio CI